Medical

Mast Therapeutics has announced that the Duke Clinical Research Institute will serve as the coordinating center for the Heart Failure Clinical Research Network (HFN) as it conducts a Phase 2 study of AIR001 sodium nitrite… Read more . . .

An analysis of data from Boehringer Ingelheim’s WISDOM study showed that withdrawal of ICS for COPD patients using the Spiriva Handihaler tiotropium bromide DPI plus salmeterol is associated with a higher exacerbation rate in patients… Read more . . .

In a leading article published in the Archives of Disease in Childhood, Andrew Bush and Louise Fleming of Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College London assert that “the diagnosis… Read more . . .

Verona Pharma has announced positive data from a Phase 2a study of RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. According to the company, asthma patients who received the… Read more . . .

The US Department of Health and Human Services has announced that a grant of up to $200,000 is available for “Assessment of Intersubject Variability in Small Airway Delivery with Oral Inhalation Drug Products.” One grant… Read more . . .

Sunovion is presenting observational study data at the Hospital Medicine 2016 conference showing that a substantial number of COPD patients are discharged from hospitals with a prescription for a dry powder inhaler despite their inability… Read more . . .

Boehringer Ingelheim has presented data at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showing that the Spiriva Respimat tiotropium bromide soft mist inhaler improves lung function and reduces exacerbations when… Read more . . .

A study published in the British Journal of General Practice titled “Overdiagnosis of asthma in children in primary care: a retrospective analysis” found that over half of children diagnosed with asthma at several major healthcare… Read more . . .

Serendex Pharmaceuticals has announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved the company’s planned IMPALA Phase 2/3 clinical trial of Molgradex inhaled molgramostim for pulmonary alveolar proteinosis (PAP). According to the… Read more . . .